Galderma Initiates U.S. Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic... | Business Wire
Phase II clinical trial of a novel muscle relaxant in the United States. The study is investigating the safety and efficacy of Galderma’s internally developed liquid formulation of botulinum toxin in the setting of aesthetic dermatology and cosmetic surgery and will add to the existing Galderma neurotoxin franchise.
No comments:
Post a Comment